Summary The enzyme thymidine kinase is associated with DNA synthesis. Thymidine kinase serum levels were studied in normal controls (n = 20), patients with primary breast cancer (n = 60), patients with systemic breast cancer (n = 20) and as a non-cancer disease control group in patients with inflammatory gastrointestinal disorders (n = 20). Comparison of pretreatment values in the cancer patients with the normal controls showed a significant difference between the three groups in relation to stage of disease: mean values 4.22 (± 1.08), 6.22 (± 2.24) and 9.79 (± 7.56) pmol ml-'h -' for normal controls, operable breast cancer and systemic breast cancer respectively (P < 0.005; analysis of variance). Patients Thymidine kinase (TK) is a pyrimidine nucleotide salvage pathway enzyme with two isoenzyme forms, cytosolar TK (TK1) and mitochondrial TK (TK2). The former has been reported to be associated with dividing cells (Bello, 1974) while activity of TK2 has been reported to remain constant throughout the cell cycle (Adler & McAuslan, 1974) . Thymidine kinase is known to be involved in DNA replication with high TK activity reported in rapidly proliferating tissues (Taylor et al., 1972; Nawata & Kamiya, 1975; Sakamoto et al., 1984 Sakamoto et al., , 1985 .
Summary The enzyme thymidine kinase is associated with DNA synthesis. Thymidine kinase serum levels were studied in normal controls (n = 20), patients with primary breast cancer (n = 60), patients with systemic breast cancer (n = 20) and as a non-cancer disease control group in patients with inflammatory gastrointestinal disorders (n = 20). Comparison of pretreatment values in the cancer patients with the normal controls showed a significant difference between the three groups in relation to stage of disease: mean values 4.22 (± 1.08), 6.22 (± 2.24) and 9.79 (± 7.56) pmol ml-'h -' for normal controls, operable breast cancer and systemic breast cancer respectively (P < 0.005; analysis of variance). Patients with systemic breast cancer had a significantly elevated serum thymidine kinase level compared to controls (P <0.01) and patients with primary operable cancer (P <0.05). Patients with primary operable cancer had significantly higher serum thymidine kinase levels over normal controls (P <0.01). Mean serum TK in patients with inflammatory gastrointestinal diseases was similar to normal controls but significantly less than both patients with primary operable breast cancer and patients with systemic breast cancer. Twenty patients with operable breast cancer were followed up after primary surgery by serial 3-monthly thymidine kinase levels in the disease free interval. Four patients have developed systemic recurrence with a rise in the mean thymidine kinase value to 14.3 pmol ml-l h'-. Ten patients with advanced breast cancer had serial thymidine kinase levels measured 2-monthly during the first 6 months of primary hormone therapy. The serum values fell in all five responders (mean 9.12 -4.78 pmol ml -' h -') and rose in all five progressors (mean 8.62-38 .5 pmol ml I h '). Serum thymidine kinase reflects stage of disease in breast cancer. Serial thymidine kinase levels in patients with systemic breast cancer reflected response to systemic therapy.
Thymidine kinase (TK) is a pyrimidine nucleotide salvage pathway enzyme with two isoenzyme forms, cytosolar TK (TK1) and mitochondrial TK (TK2). The former has been reported to be associated with dividing cells (Bello, 1974) while activity of TK2 has been reported to remain constant throughout the cell cycle (Adler & McAuslan, 1974) . Thymidine kinase is known to be involved in DNA replication with high TK activity reported in rapidly proliferating tissues (Taylor et al., 1972; Nawata & Kamiya, 1975; Sakamoto et al., 1984 Sakamoto et al., , 1985 .
Serum TK has been reported to be elevated in a number of malignant conditions (Kreis et al., 1982; O'Neill et al., 1986 O'Neill et al., , 1987 Ellims et al., 1981; Eriksson et al., 1985) , including breast cancer Table I . Patients with systemic disease were significantly older than normal controls (P <0.02) and patients with operable disease (P <0.01) . Previous studies have shown no effect of age on serum total TK . However, age-matched subgroups of the controls, operable and systemic breast cancer patients were analysed for serum total TK (Table II) . (Gronowitz et al., 1984) .
Full details of the TK enzyme assay have been previously published (O'Neill et al., 1986 (Hayward et al., 1977) , adhering to the British Breast Group recommendation that the minimum duration of remission be 6 months (British Breast Group, 1974 (Table I ) (P <0.005; analysis of variance). The highest levels were found in patients with systemic breast cancer which as a group were significantly higher than both the normal controls (P <0.01) and the operable breast cancer patients (P <0.05). However, serum TK in patients with operable breast cancer was also significantly higher than in normal controls (P <0.01). Analysis of age matched subgroups showed that serum total TK levels were still elevated in patients with breast cancer (P < 0.003; analysis of variance) (Table II) .
The mean serum TK in patients with inflammatory gastrointestinal diseases was 4.83 (± 1.73) pmol ml-' h-' with mean % CTP/ATP activity of 58.6 (± 16.8) . Serum TK in this group of patients was similar to normal controls (P = 0.2) but significantly less than with patients with primary operable breast cancer (P = 0.01) and patients with systemic breast cancer (P = 0.01).
The mean (± s.d.) for the 60 patients with operable breast cancer was 6.22 (± 2.24). The pre-surgery serum TK value of the three prognostic groups (good, moderate and poor) were analysed and found to be 6.32 (± 2.48), 6.21 (± 1.88) and 5.95 (± 2.40) respectively ( Tables IV and V . In four of the five responders serum TK values moved from above the cut-off level pretreatment to below the cut-off level indicative of response by our assessment criteria: decrease in serum TK of 63%, 56%, 43% and 25% were well above the coefficient of variation (Table IV) . In the remaining patient serum TK remained below the cut-off level throughout treatment. In four of the five progressors serum TK started above the cut-off level and increased by 907%, 178%, 155% and 70%, indicative of progression (Table V) . In the remaining patient serum TK started and finished above the cut-off level with a change of + 1% representing 'biochemically stable' disease.
By measuring the % CTP/ATP TK activity it is possible to assess whether any increase in serum TK activity is due mainly to an increase in TK 1, TK2 or a combination of both. The pre-treatment mean % CTP/ATP TK activity for patients in the normal controls, operable disease and systemic disease groups are shown in Table I .
The patterns of serum TKI and TK2 were analysed in patients who had serial serum TK measurements and found to be similar between the patients in the poor prognostic group who developed recurrence on follow-up and those who did not. The pattern of TK1 and TK2 was also similar in the groups of patients with systemic disease who responded and who progressed. In all the groups elevation of serum TK Mean TK + 2 s.d. of normal control group = 6.4 pmol ml-' h-'. (Kreis et al., 1982; O'Neill et al., 1986 O'Neill et al., , 1987 Ellims et al., 1981; Eriksson et al., 1985; McKenna et al., 1988) . This study shows that TK is significantly elevated in the serum of breast cancer patients when compared both to normal controls and to patients with inflammatory gastrointestinal diseases. Serum TK levels are significantly higher in patients with systemic disease compared to patients with operable primary breast cancer (Table I) Mean TK + 2 s.d. or normal control group = 6.4 pmol ml-' h-'.
age was not a factor in the increased serum TK levels in patients with systemic breast cancer: serum TK levels were significantly higher in patients with operable disease compared to normal controls although age in both groups was similar. In addition analysis of age matched subgroups of the controls, operable and advanced breast cancer patients showed that serum TK was still elevated for stage of disease (Table II) . This confirms previous work showing no age effect on serum TK levels . Serum TK has been shown to be elevated in a number of other malignancies. We have tried to examine whether elevation of serum TK is also found in non-cancerous conditions as a reflection of increased cell turnover/proliferation such as might be expected with acute inflammatory gastrointestinal diseases. The mean serum TK in the group of patients with inflammatory gastrointestinal diseases was similar to that in normal controls, and like the normal controls was significantly less than patients with primary operable breast cancer and systemic breast cancer. Further work investigating serum TK in other control groups (e.g. chronic diseases such as chronic obstructive airways disease, congestive cardiac failure and rheumatoid arthritis) would be of interest but is beyond the scope of this preliminary report.
Serum TK levels in patients with primary operable breast cancer were not related to prognosis as measured by the Nottingham prognostic index for primary breast cancer (Todd et al., 1987) (Table I) .
The percentage of TKI and TK2 making up the total serum TK was similar in all three prognostic groups as indicated by similar % CTP/ATP TK activities (Table I) . Therefore while serum TK may be of diagnostic value in primary operable disease, neither serum TK nor the relative % TKI or % TK2 are of prognostic value at this stage of disease.
In systemic disease our results suggest that both isoenzymes TKI and TK2 are elevated although the increase in TK I activity appears slightly greater as indicated by the cancer patients having lower % CTP/ATP TK activities than controls. These results confirm a previous report by McKenna and colleagues. Other malignancies have been reported to be associated with greater increases in serum TKI than in TK2, a finding in keeping with the observation that TKI is associated with dividing cells (Bello, 1974) . The significance of elevation of both TKI and TK2 in breast cancer is uncertain at present. However, Sakamoto and colleagues (1986) found both forms of TK to be elevated in human mammary tumours, albeit with a greater relative increase in TK 1.
The source of the elevated serum TK is as yet uncertain. It may be due to a combination of the release of TK due to cancer cell death (such cells may not be dividing rapidly at the time of death), leakage of TK from rapidly dividing cancer cells (this would favour an increase in TK1 relative to TK2) and release of TK from normal cell death as part of tumour associated tissue destruction (this might have no effect on the ratio of the two enzymes).
Serial serum samples during the disease-free interval of 20 primary operable patients in the poor prognostic group showed that serum TK reflect rather than predicts recurrent disease.
Pre-treatment TK activity did not predict which patients with systemic disease would respond or progress (mean pretreatment TK value 9.1 and 8.6 respectively) on endocrine therapy.
Changes in serum TK correctly reflected clinical response in four out of five responders, with the remaining patient being biochemically unassessable. In four out of five progressors changes in serum TK correctly reflected clinical progression with the remaining patient having an elevated though stable serum TK. Eight patients were therefore correctly assessed using serum TK measurements, one patient was biochemically unassessable and the remaining patient showed a persistently elevated though stable marker rather than an increasing serum TK level. Changes in serial TK above the coefficient of variation occurred in four out of five responders and progressors (Tables IV and V) . Serum TK appears to be a useful marker in monitoring therapy in patients with systemic breast cancer.
It has been reported that cultures of rapidly proliferating tumour cells release TK into the surrounding medium (Bristow et al., 1988) and it is thought that TK is released from tumour cells into the circulation (Kreis et al., 1982) . Our results showing an increase in serum TK activity in patients with progressive disease would be consistent with this experimental work. The correlation between serial serum TK levels and response to therapy is an interesting finding and requires confirmation with a larger number of patients.
Serum TK appears a potentially important marker in systemic breast cancer in that TK values in patients with systemic disease was significantly higher than in patients with operable breast cancer, normal controls or patients with acute inflammatory gastrointestinal diseases. Serial changes in serum TK in patients with systemic disease reflect response to endocrine therapy.
